1. Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1
   Sanjeev Kumar et al, 2019, Journal of Medicinal Chemistry CrossRef
2. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
   Anne M. Macpherson et al, 2020, Journal of Clinical Medicine CrossRef
3. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
   Adaobi Amobi-McCloud et al, 2021, Frontiers in Immunology CrossRef
4. Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
   Lukas Lanser et al, 2020, Frontiers in Immunology CrossRef
5. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
   Suat Sari et al, 2019, Molecules CrossRef
6. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
   Galaxia Rodriguez et al, 2018, Cancers CrossRef
7. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
   Marie Christine Wulff Westergaard et al, 2020, Cancers CrossRef
8. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
   Yvonne Grobben et al, 2021, Frontiers in Immunology CrossRef
9. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
   Takemasa Tsuji et al, 2020, Oncotarget CrossRef
10. Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients
    Kashif Asghar et al, 2020, World Journal of Clinical Oncology CrossRef
11. IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
    Houmei Wang et al, 2022, International Journal of Molecular Sciences CrossRef
12. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
    Theodoros Eleftheriadis, 2018, Frontiers in Immunology CrossRef